A study to look at how well emicizumab works when given every 1, 2, or 4 weeks to prevent bleeds in people with mild or moderate haemophilia A without factor 8 inhibitors

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors